In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

On Monday, BTIG updated its outlook on Exact Sciences Corp (NASDAQ:EXAS), increasing the price target to $82 from the previous $70 while reiterating a Buy rating on the stock. The adjustment ...

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease.

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out that marks the first Spanish-language promotional push for the brand.

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity Scientific insights reflect Exact Sciences’ commitment to closing the ...

US diagnostic company Exact Sciences has announced its blood-based colorectal cancer (CRC) screening test algorithm showed a sensitivity of 88% for colorectal cancer and 31% for advanced ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal ...